Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India.
India
Italy
Takayasu arteritis
aortic arch syndromes
arteritis
healthcare disparities
systemic vasculitis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
received:
09
10
2022
revised:
08
11
2022
accepted:
06
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
The present study compares disease characteristics, imaging modalities used, and patterns of treatment in two large cohorts of Takayasu arteritis (TAK) from Italy and India. Clinic files were retrospectively reviewed to retrieve information about initial choices of vascular imaging and immunosuppressive therapies. Unpaired t-tests compared means, and proportions were compared using Fisher’s exact test or Chi square test [Odds ratios (OR) with 95% confidence intervals (95%CI) calculated where appropriate]. The cohorts comprised 318 patients [Italy (n = 127), India (n = 191)] with similar delays to diagnosis. Ultrasound (OR Italy vs. India 9.25, 95%CI 5.02−17.07) was more frequently used in Italy and CT angiography in India (OR 0.32, 95%CI 0.20−0.51). Corticosteroid use was more prevalent and for longer duration in Italy. TAK from Italy had been more often treated with methotrexate, leflunomide or azathioprine, as opposed to tacrolimus in TAK from India (p < 0.05). Biologic or targeted synthetic disease-modifying agents were almost exclusively used in Italy. Survival on first immunosuppressive agent was longer from Italy than from India (log rank test p value 0.041). Considerable differences in the choice of initial vascular imaging modality and therapies for TAK from Italy and India could relate to prevalent socio-economic disparities. These should be considered while developing treatment recommendations for TAK.
Identifiants
pubmed: 36553110
pii: diagnostics12123102
doi: 10.3390/diagnostics12123102
pmc: PMC9777621
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Senior Research Fellowship from the Indian Council of Medical Research
ID : 3/1/1(20)/2022-NCD-I
Références
Mod Rheumatol. 2021 May;31(3):678-683
pubmed: 32700985
Rheumatology (Oxford). 2013 Oct;52(10):1795-801
pubmed: 23594468
Rheumatology (Oxford). 2020 Jul 1;59(7):1617-1621
pubmed: 31665468
Mayo Clin Proc. 2013 Aug;88(8):822-30
pubmed: 23849994
Mod Rheumatol. 2022 Sep 03;:
pubmed: 36057089
Ann Rheum Dis. 2020 Jan;79(1):19-30
pubmed: 31270110
Clin Exp Rheumatol. 2011 Jan-Feb;29(1 Suppl 64):S40-2
pubmed: 21385546
J Rheumatol. 2010 Mar;37(3):512-20
pubmed: 20080907
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1109-1118
pubmed: 28180963
Can J Cardiol. 2020 Apr;36(4):535-542
pubmed: 31924450
Semin Arthritis Rheum. 2018 Apr;47(5):718-726
pubmed: 29096935
Mod Rheumatol. 2022 Feb 28;32(2):406-412
pubmed: 34894247
Diagnostics (Basel). 2022 Oct 21;12(10):
pubmed: 36292253
Circ Res. 2019 Mar 29;124(7):1124-1140
pubmed: 30920917
Mod Rheumatol. 2022 Apr 19;:
pubmed: 35438750
Rheumatology (Oxford). 2010 Oct;49(10):1889-93
pubmed: 20542893
Scand J Rheumatol. 2012 May;41(3):227-30
pubmed: 22400913
Rheumatology (Oxford). 2021 May 14;60(5):2246-2255
pubmed: 33179052
Autoimmun Rev. 2016 Jun;15(6):544-51
pubmed: 26883459
Ann Intern Med. 1994 Jun 1;120(11):919-29
pubmed: 7909656
Curr Hypertens Rep. 2016 Nov;18(11):80
pubmed: 27787835
Health Syst Transit. 2014;16(4):1-168
pubmed: 25471543
Arthritis Care Res (Hoboken). 2021 Aug;73(8):1071-1087
pubmed: 34235871
Clin Exp Rheumatol. 2021 Mar-Apr;39 Suppl 129(2):129-134
pubmed: 33666154
Nat Rev Dis Primers. 2022 Jan 6;7(1):93
pubmed: 34992251
Clin Rheumatol. 2021 Nov;40(11):4391-4416
pubmed: 33932173
Int J Cardiol. 1996 Aug;54 Suppl:S99-102
pubmed: 9119532
Indian J Radiol Imaging. 2021 Apr;31(2):259-264
pubmed: 34556905
Curr Rheumatol Rep. 2020 Oct 16;22(12):86
pubmed: 33067687
Rheumatol Int. 2021 Oct;41(10):1729-1742
pubmed: 34302232
Rev Bras Reumatol Engl Ed. 2016 Jul-Aug;56(4):371-5
pubmed: 27476631
Semin Arthritis Rheum. 2020 Jun;50(3):509-514
pubmed: 32088012
Rheumatol Int. 2018 Dec;38(12):2263-2270
pubmed: 30182290
Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S59-64
pubmed: 19646348
CVIR Endovasc. 2018;1(1):8
pubmed: 30652141
Int J Cardiol. 1996 Aug;54 Suppl:S155-63
pubmed: 9119518
Rheumatology (Oxford). 2022 Apr 11;61(4):1376-1384
pubmed: 34363461
Front Med (Lausanne). 2021 Sep 27;8:723506
pubmed: 34646844
J Rheumatol. 2014 Dec;41(12):2439-46
pubmed: 25274886
Int J Rheum Dis. 2019 Jan;22 Suppl 1:60-68
pubmed: 30698358
AJR Am J Roentgenol. 2018 Oct;211(4):730-735
pubmed: 30063369
Circulation. 2017 Sep 19;136(12):1114-1122
pubmed: 28701469
Scand J Rheumatol. 2019 Nov;48(6):482-490
pubmed: 31064248
Semin Arthritis Rheum. 2022 Apr;53:151971
pubmed: 35104688
J Hum Genet. 2016 Jan;61(1):27-32
pubmed: 26178430
Arthritis Rheum. 1990 Aug;33(8):1129-34
pubmed: 1975175
Clin Rheumatol. 2010 Sep;29(9):973-81
pubmed: 20589520
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Rheumatology (Oxford). 2022 Nov 28;61(12):4885-4891
pubmed: 35262635
Curr Opin Rheumatol. 2015 Jan;27(1):32-7
pubmed: 25405824
Rheumatol Int. 2017 Jul;37(7):1065-1073
pubmed: 28224216
Rheumatol Int. 2022 Aug;42(8):1347-1354
pubmed: 34993577
Rheumatology (Oxford). 2022 Oct 6;61(10):4047-4055
pubmed: 35022691
Semin Arthritis Rheum. 2021 Dec;51(6):1224-1229
pubmed: 34706312
Medicine (Baltimore). 2010 Jan;89(1):1-17
pubmed: 20075700
Rheumatol Int. 2018 Sep;38(9):1587-1600
pubmed: 30022301
Rheumatol Int. 2012 Mar;32(3):703-9
pubmed: 21152919
Ann Rheum Dis. 2010 May;69(5):798-806
pubmed: 20413568
Rheumatology (Oxford). 2022 Apr 18;61(SI):SI4-SI5
pubmed: 34373894
J Inflamm Res. 2022 Mar 01;15:1521-1541
pubmed: 35256852
Ann Rheum Dis. 2018 May;77(5):636-643
pubmed: 29358285
Rheumatol Adv Pract. 2018 Aug 16;2(2):rky026
pubmed: 31431972
Semin Arthritis Rheum. 2020 Aug;50(4):576-581
pubmed: 32460147
Rheumatology (Oxford). 2018 Dec 1;57(12):2101-2105
pubmed: 30010945